A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This open-label study will evaluate the safety, pharmacokinetics and antiviral activity of a
modified Invirase (saquinavir)/ritonavir regimen in treatment-naïve HIV-1 infected patients.
Patients will receive Invirase 500 mg plus ritonavir 100 mg twice daily orally for the first
week, followed by Invirase 1000 mg plus ritonavir 100 mg twice daily orally for the second
week. The study treatment will be given in combination with two Nucleoside Reverse
Transcriptase Inhibitors (NRTIs), in accordance with the current clinical HIV treatment
guidelines. Anticipated time on study treatment is 14 days.